



I G PETROCHEMICALS LIMITED

SECT/1042

30th May, 2018

BSE Limited

Corporate Relationship Department
1st Floor, P J Towers
Dalal Street
Mumbai - 400 001

Scrip Code: 500199

The National Stock Exchange of India Ltd.

Exchange Plaza
Bandra Kurla Complex
Bandra (East)
Mumbai - 400 051

Scrip Code: IGPL

Dear Sir,


Sub : Investor Presentation – Regulation 30

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith an Investor Presentation on Audited Financial Results of the Company for the quarter and year ended 31st March, 2018.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,
For I G Petrochemicals Limited


Sudhir R Singh

Company Secretary



Encl : as above



IG PETROCHEMICALS LIMITED

Q4 FY18 Result Presentation – May 2018

- ❑ About Us
- ❑ Our Journey
- ❑ Vision 2025
- ❑ Key Competitive Strengths
- ❑ Location Advantage
- ❑ Large Customer Base
- ❑ Ongoing Expansion
- ❑ Industry Overview
- ❑ Financial Highlights
- ❑ CSR Activities



About Us



India's Largest Phthalic Anhydride (PAN) manufacturer and one of the Leaders across the Globe

PAN is a downstream product of Orthoxylene (OX) a basic Petrochemical

PAN is a versatile intermediate in organic chemistry for production of Plasticizers, Unsaturated Polyester Resins, Alkyd Resins, Paints & CPC Pigments

Plants are engineered with modern technologies and are designed on the low energy based processes
Steam generated from the production process used for Company's captive power requirements

Usage of PAN is increasing in new generation products where R & D is ongoing


We are an environmentally responsible Company

IGPL produces Maleic Anhydride through wash water generated out of the production process of PAN.
Maleic Anhydride is used in agro and food businesses

IGPL also manufactures Benzoic Acid (BA) as a by product



Our Journey...



* For an initial period of 10 years


PA – Phthalic Anhydride; MA – Maleic Anhydride; BA – Benzoic Acid; MTPA – Metric Tonnes per annum; MPCL – Mysore Petro Chemicals Ltd.



“ To be the Largest Manufacturer of Phthalic Anhydride in the World ”



Key Competitive Strengths





Location Advantage






Large Customer Base





Ongoing Expansion



Expansion to come on-stream in 2019




Industry Overview



INDIAN MARKET SIZE

Phthalic Anhydride is ~3,75,000 MTPA
Maleic Anhydride (MA) is ~60,000 MTPA



INDUSTRY GROWTH

PA to grow domestically 5% - 6% annually, backed by the thrust on Infrastructure and GDP growth
MA also expected to grow 6% - 7% in the next few years

INFRASTRUCTURE DEVELOPMENT

Highest Budget by the government for Infrastructure Development at Rs. 3.96 lakh crores

UNIQUE POSITION for IGPL


The Company is uniquely positioned to partake in the industry growth




Financial Highlights - Q4 FY18




Revenue (Rs. Crores) ^




EBITDA (Rs. Crores) ^




PAT (Rs. Crores)



EBITDA (%)



PAT (%)



The Financial Results for Q4 FY18 have been prepared in accordance with the Indian Accounting Standards (Ind AS)


^ Includes Other Income




Financial Highlights – FY18




Revenue (Rs. Crores) ^




EBITDA (Rs. Crores) ^




PAT (Rs. Crores)



EBITDA (%)



PAT (%)



The Financial Results for FY18 have been prepared in accordance with the Indian Accounting Standards (Ind AS)


^ Includes Other Income




Financial Highlights




Revenue (Rs. Crores)#




EBITDA (Rs. Crores) and Margin %




PAT (Rs. Crores) and Margin %




Net Debt (Rs. Lakhs) & Net Debt / Equity



D



ROCE %



Includes Other Income

The Financial Results for FY18 have been prepared in accordance with the Indian Accounting Standards (Ind AS)



Profit & Loss Statement – FY18



st	r	r	dr
d d d	d st r	8%	10%
D	?	36%	58%
EBITDA Margin (%)	20.7%	16.5%	23.6%
D			
EBIT Margin (%)	18.5%	14.8%	21.4%
st d d		43%	75%
st st		17%	44%
PAT Margin (%)	10.6%	9.8%	12.8%
?	D D R D D		

The Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS)

* Standalone

^ Includes Other Income



Balance Sheet - March 2018



st r r dr		
D st		
st D st		
d st stdr		
st d st stdr		
d st stdr		
st d st stdr		
st D st ch stdr		

st r r dr		
d st rrdst		
rrdst		
st d st rrdst		
d st rrdst		
rrdst		
st d st rrdst		
st rrdst		

The Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS)

* Standalone



CSR Activities



- ☐ Construction of a school in Vrindavan for providing education to the underprivileged children
- ☐ Educating the poor, annadhanam (feeding of poor), free /concessional health care to the needy apart from other charitable activities
- ☐ Sustainability of environment viz. transplantation of trees, water conservation projects, environment protection awareness campaign titled 'Say no to plastic', mobile toilet etc.
- ☐ Contribution to Charitable Trust and Community organisation i.e. old age homes, Blind Organization of India, etc.



Safe Harbor



This presentation has been prepared by and is the sole responsibility of I G Petrochemicals Limited (the “Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Certain statements contained in this presentation that are not statements of historical fact constitute “forward-looking statements.” You can generally identify forward-looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.

For further information, please contact

Dr. St. d. St. r. ch r. r.

Dr. St. d. r. St.

Dr. St. St. St. ch r. r. St. St.